MapLight Therapeutics, Inc. Common Stock (MPLT) — Cash Flow-to-Debt Ratio
MapLight Therapeutics, Inc. Common Stock (MPLT) has a Cash Flow-to-Debt Ratio of -2.24x as of June 2026, meaning its operating cash flow of $-44.87 Million could theoretically repay -2% of its total liabilities ($20.05 Million) in one year. See how financially flexible is MapLight Therapeutics, Inc. Common Stock to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
MapLight Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio (2022–2025)
Historical debt coverage capacity for MapLight Therapeutics, Inc. Common Stock across 4 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of MapLight Therapeutics, Inc. Common Stock.
Annual Cash Flow-to-Debt Ratio for MapLight Therapeutics, Inc. Common Stock (2022–2025)
Year-by-year debt coverage analysis for MapLight Therapeutics, Inc. Common Stock.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -6.53x | $-138.14 Million | $21.14 Million | ▼ -80.1% |
| 2024 | -3.63x | $-78.81 Million | $21.72 Million | ▼ -40.4% |
| 2023 | -2.58x | $-52.01 Million | $20.13 Million | ▼ -80.0% |
| 2022 | -1.44x | $-26.58 Million | $18.52 Million | — |